These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Novel Pyrazolo[3,4-d]pyrimidines as Potential Cytotoxic Agents: Design, Synthesis, Molecular Docking and CDK2 Inhibition. Maher M; Kassab AE; Zaher AF; Mahmoud Z Anticancer Agents Med Chem; 2019; 19(11):1368-1381. PubMed ID: 31038080 [TBL] [Abstract][Full Text] [Related]
4. Synthesis and in vitro antiproliferative activity of C5-benzyl substituted 2-amino-pyrrolo[2,3-d]pyrimidines as potent Hsp90 inhibitors. Lee JH; Shin SC; Seo SH; Seo YH; Jeong N; Kim CW; Kim EE; Keum G Bioorg Med Chem Lett; 2017 Jan; 27(2):237-241. PubMed ID: 27914802 [TBL] [Abstract][Full Text] [Related]
5. Synthesis, EGFR Inhibition and Anti-cancer Activity of New 3,6-dimethyl-1-phenyl-4-(substituted-methoxy)pyrazolo[3,4-d] pyrimidine Derivatives. Bakr RB; Mehany ABM; Abdellatif KRA Anticancer Agents Med Chem; 2017; 17(10):1389-1400. PubMed ID: 28270084 [TBL] [Abstract][Full Text] [Related]
6. Discovery of 5-aryl-3-thiophen-2-yl-1H-pyrazoles as a new class of Hsp90 inhibitors in hepatocellular carcinoma. Mohamady S; Ismail MI; Mogheith SM; Attia YM; Taylor SD Bioorg Chem; 2020 Jan; 94():103433. PubMed ID: 31785857 [TBL] [Abstract][Full Text] [Related]
7. Identification and optimization of novel Hsp90 inhibitors with tetrahydropyrido[4,3-d]pyrimidines core through shape-based screening. Sun HP; Jia JM; Jiang F; Xu XL; Liu F; Guo XK; Cherfaoui B; Huang HZ; Pan Y; You QD Eur J Med Chem; 2014 May; 79():399-412. PubMed ID: 24763261 [TBL] [Abstract][Full Text] [Related]
13. Novel pyrazole-5-carboxamide and pyrazole-pyrimidine derivatives: synthesis and anticancer activity. Shi JB; Tang WJ; Qi XB; Li R; Liu XH Eur J Med Chem; 2015 Jan; 90():889-96. PubMed ID: 25554922 [TBL] [Abstract][Full Text] [Related]
14. Synthesis, anticancer evaluation, and molecular docking studies of some novel 4,6-disubstituted pyrazolo[3,4-d]pyrimidines as cyclin-dependent kinase 2 (CDK2) inhibitors. Cherukupalli S; Chandrasekaran B; Kryštof V; Aleti RR; Sayyad N; Merugu SR; Kushwaha ND; Karpoormath R Bioorg Chem; 2018 Sep; 79():46-59. PubMed ID: 29753773 [TBL] [Abstract][Full Text] [Related]
15. Synthesis, design, and antiproliferative evaluation of 6-(N-Substituted-methyl)pyrazolo[3,4-d]pyrimidines as the potent anti-leukemia agents. Chung CY; Li SM; Zeng WZ; Uramaru N; Huang GJ; Juang SH; Wong FF Bioorg Chem; 2024 Jul; 148():107424. PubMed ID: 38728908 [TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and pharmacological evaluation of ALK and Hsp90 dual inhibitors bearing resorcinol and 2,4-diaminopyrimidine motifs. Geng K; Liu H; Song Z; Zhang C; Zhang M; Yang H; Cao J; Geng M; Shen A; Zhang A Eur J Med Chem; 2018 May; 152():76-86. PubMed ID: 29698859 [TBL] [Abstract][Full Text] [Related]
17. Drug Design, Synthesis and In Vitro Evaluation of Substituted Benzofurans as Hsp90 Inhibitors. Kadasi S; Costa TEMM; Arukala N; Toshakani M; Duggineti C; Thota S; Dutta Gupta S; Raj S; Penido C; Henriques MG; Raghavendra NM Med Chem; 2018; 14(1):44-52. PubMed ID: 28641528 [TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and anticancer evaluation of 1H-pyrazolo[3,4-d]pyrimidine derivatives as potent EGFR Gaber AA; Bayoumi AH; El-Morsy AM; Sherbiny FF; Mehany ABM; Eissa IH Bioorg Chem; 2018 Oct; 80():375-395. PubMed ID: 29986185 [TBL] [Abstract][Full Text] [Related]
19. Design and synthesis of pyrimidinyl acyl thioureas as novel Hsp90 inhibitors in invasive ductal breast cancer and its bone metastasis. Koca İ; Özgür A; Er M; Gümüş M; Açikalin Coşkun K; Tutar Y Eur J Med Chem; 2016 Oct; 122():280-290. PubMed ID: 27376491 [TBL] [Abstract][Full Text] [Related]
20. Quinazoline Based HSP90 Inhibitors: Synthesis, Modeling Study and ADME Calculations Towards Breast Cancer Targeting. El-Shafey HW; Gomaa RM; El-Messery SM; Goda FE Bioorg Med Chem Lett; 2020 Aug; 30(15):127281. PubMed ID: 32527460 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]